{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:49:21Z","timestamp":1788274161787,"version":"build-2803163510"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T00:00:00Z","timestamp":1460332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00262-016-1835-4","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T08:53:00Z","timestamp":1460623980000},"page":"765-767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome"],"prefix":"10.1007","volume":"65","author":[{"given":"Elizabeth","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Sahasrabudhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Sievert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,11]]},"reference":[{"issue":"6","key":"1835_CR1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","volume":"64","author":"J Martin-Liberal","year":"2015","unstructured":"Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J (2015) Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 64(6):765\u2013767. doi: 10.1007\/s00262-015-1689-1","journal-title":"Cancer Immunol Immunother"},{"key":"1835_CR2","unstructured":"Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2015) \u00a0"},{"key":"1835_CR3","unstructured":"Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2015)"},{"key":"1835_CR4","unstructured":"Pembrolizumab (keytruda) [package insert]. Whitehouse Station, NJ: Merk & Co., Inc. (2015)"},{"key":"1835_CR5","unstructured":"Keytruda (pembrolizumab) [package insert]. Merck & Co., Inc., Whitehouse Station, NJ (2014)"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1835-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-016-1835-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1835-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:33:29Z","timestamp":1558715609000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-016-1835-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,11]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["1835"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1835-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,11]]}}}